Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Operating Expenses of $372.4 million for Q1 2026, down 64.37% year-over-year from $1.0 billion in Q1 2025, and down 56.42% quarter-over-quarter from $854.5 million in Q4 2025.
Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $372.4 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 64.37% year-over-year to $372.4 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 5.34% YoY), while the FY2025 annual figure was $2.9 billion, up 72.1% from the prior year.
- Operating Expenses for Q1 2026 stood at $372.4 million, down from $854.5 million in the prior quarter.
- The five-year high for Operating Expenses was $1.0 billion in Q1 2025, with the low at $297.7 million in Q1 2022.
- The 5-year median for Operating Expenses is $391.6 million (2023), against an average of $466.7 million.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 176.11% in 2025, then slumped 64.37% in 2026.
- Sarepta Therapeutics' Operating Expenses stood at $365.3 million in 2022, then gained by 1.89% to $372.2 million in 2023, then surged by 33.47% to $496.7 million in 2024, then jumped by 72.03% to $854.5 million in 2025, then tumbled by 56.42% to $372.4 million in 2026.
- Business Quant data shows SRPT's Operating Expenses at $372.4 million in Q1 2026, $854.5 million in Q4 2025, and $502.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 387.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387.96 Mn |
| Mar 31, 2026 | 372.37 Mn |
| Dec 31, 2025 | 854.52 Mn |
| Sep 30, 2025 | 502.75 Mn |
| Jun 30, 2025 | 495.51 Mn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 496.73 Mn |
| Sep 30, 2024 | 444.98 Mn |
| Jun 30, 2024 | 363.63 Mn |
| Mar 31, 2024 | 378.56 Mn |
| Dec 31, 2023 | 372.16 Mn |
| Sep 30, 2023 | 352.66 Mn |
| Jun 30, 2023 | 394.76 Mn |
| Mar 31, 2023 | 391.59 Mn |
| Dec 31, 2022 | 365.26 Mn |
| Sep 30, 2022 | 361.62 Mn |
| Jun 30, 2022 | 444.62 Mn |
| Mar 31, 2022 | 297.71 Mn |
| Dec 31, 2021 | 307.27 Mn |
| Sep 30, 2021 | 223.86 Mn |